Símbolos

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

APLS(Quitar la ciudad)

Apellis·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About APLS

Apellis Pharmaceuticals, Inc.

A commercial-stage biopharmaceutical company focused on the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade

Industry

Established Date

09/25/2009

Listing Date

11/09/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

733

Fiscal Year Ends

12-31

Website

www.apellis.com

Security Type

Common stock

Office address

100 Fifth Avenue , Waltham , MA 02451

Business

Discovers, develops and commercializes complement system inhibitors.

Introduction

Apellis Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on September 25, 2009. The Company is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds for the treatment of diseases with high unmet need by inhibiting the complement system (as a component of the immune system) at the level of central protein C3 in the complement cascade. In February 2023, the U.S. Food and Drug Administration (FDA) approved SYFOVRE, the first drug approved for the treatment of geographic atrophy secondary to age-related macular degeneration (GA).

Company Financials

EPS

APLS has released its 2025 Q4 earnings. EPS was reported at 0.47, versus the expected -0.38, beating expectations. The chart below visualizes how APLS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

APLS has released its 2026 Q1 earnings report, with revenue of 268.30M, reflecting a YoY change of 60.85%, and net profit of 18.66M, showing a YoY change of 120.23%. The Sankey diagram below clearly presents APLS's revenue sources and cost distribution.